Abstract

A New Market for POC Technologies: Analytics for Autologous Gene Therapies

Chaminda Salgado, Cell & Gene Therapy Medicinal Process Delivery Leader, GlaxoSmithKline

Autologous gene therapies provides the POC Dx sector with a new, unique and very lucrative opportunity to deploy their technology, rapidly, for use by the pharmaceutical sector. This sector is in urgent need of fully automated, rapid sample to result tests, using patient material as the sample. This requirement is very familiar with the POC Dx sector, and exploiting this opportunity enables such technology to be deployed more rapidly for commercialisation than for the diagnostic sector, as there is no need for clinical trail studies, seeking of regulatory approval, and even the full validation is a burden for the client.